ArticleThe American journal of tropical medicine and hygiene2025
Uropathogens and Their Antimicrobial Resistance Profile at a Pediatric Tertiary Care Hospital in Kathmandu, Nepal.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Distribution and antibiotic resistance profiles of uropathogens at Madan Bhandari Hospital, Nepal: Focus on multidrug and extensively drug-resistant strains.IJID regions · 2026Article
- Phenotypic Fosfomycin Susceptibility and Detection of Plasmid-Mediated Resistance Genes in Clinical UropathogenicMicroorganisms · 2026Article
- Burden of antibiotic resistance in urinary isolates: a retrospective cross-sectional study from a tertiary center in Far-Western Nepal.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs) are treated based on local antimicrobial susceptibility patterns; however, growing antimicrobial resistance necessitates continuous monitoring. This retrospective study examined the prevalence of pediatric UTIs, identified causative pathogens, and evaluated their antibiograms and resistance patterns. We examined the demographic data, microbiological profiles, and antimicrobial susceptibility results (September 2019-August 2021) of pediatric patients (neonates to 14 years) with positive urine culture results at Kanti Children's Hospital, Kathmandu, Nepal, using SPSS version 17.0 (IBM Corp., Armonk, NY). Among 8,072 urine specimens, 575 (7.1%) (95% CI: 6.6-7.7) tested positive for significant infections, primarily from outpatients (88.2%) and males (54.1%), with a median age of 2 years. Most UTIs (93.0%; 535/575) were caused by bacteria, primarily Escherichia coli (78.5%; 420/535). Cumulative resistance rates were 92.4% for penicillin, 69.3% for cephalosporins, 39.7% for quinolones, 30.2% for carbapenems, and 14.3% for aminoglycosides. One hundred sixty-eight (40.0%) E. coli strains and four (33.3%) Pseudomonas aeruginosa strains were multidrug-resistant. Seven (9.0%) Klebsiella pneumoniae strains were extensively drug-resistant (XDR), and 15 (21.1%) were extended-spectrum β-lactamase (ESBL) producers. Multidrug-resistant strains (36.5%; 210/575), XDR strains (22.6%; 15/575), and ESBL producers (14.4%; 83/575) showed >70.0% resistance to ampicillin, cefotaxime-clavulanate, and cefixime. Over the years, resistance to β-lactams has risen, whereas resistance to aminoglycosides, carbapenems, and cotrimoxazole has decreased. Resistance to quinolones has remained consistent. Pediatric UTIs were least common in this hospital, with the majority caused by E. coli. Multidrug-resistant bacteria were more prevalent than XDR and ESBL-producing bacteria. Although resistance to β-lactam antibiotics increased over the years, resistance to aminoglycosides, carbapenems, and cotrimoxazole declined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.